Related Experiment Video

Updated: May 12, 2026

In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus
11:59

In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus

Published on: April 28, 2023

[Effect of propranolol gel on infantile hemangiomas]

Ya-Nan Zhai1, Hong-Tao Song, Shao-Quan Chen

  • 1Department of General Surgery, Fuzhou General Hospital of Nanjing Military Command, Fuzhou 350025, China.

Zhonghua Zheng Xing Wai Ke Za Zhi = Zhonghua Zhengxing Waike Zazhi = Chinese Journal of Plastic Surgery
|April 23, 2013
PubMed

Insights

Topical propranolol hydrochloride 3% gel effectively treats infantile hemangiomas, particularly superficial types. This treatment offers a promising therapeutic option for improving hemangioma outcomes.

Area of Science:

  • Dermatology
  • Pediatrics
  • Pharmacology

Context:

  • Infantile hemangiomas (IHs) are common vascular tumors in infants.
  • Treatment options for IHs have evolved, with a focus on non-invasive methods.
  • Propranolol has emerged as a key therapeutic agent for IHs.

Purpose:

  • To assess the efficacy and safety of propranolol hydrochloride 3% gel for treating infantile hemangiomas.
  • To evaluate treatment response based on size, texture, color, and blood flow.
  • To determine if superficial hemangiomas respond differently to topical propranolol.

Summary:

  • A study involving 51 infants with hemangiomas treated with propranolol hydrochloride 3% gel.
  • Treatment outcomes were evaluated using the Achauer system, with significant improvement observed in most patients.
  • Superficial hemangiomas showed a significantly better response to the gel compared to other types.

Impact:

  • Topical propranolol hydrochloride 3% gel represents an effective and potentially safer alternative for managing infantile hemangiomas.
  • The findings support the use of this gel, especially for superficial IHs, potentially reducing the need for systemic therapy.
  • This research contributes to the understanding of localized treatment strategies for pediatric vascular anomalies.
Abstract

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...